Andrew Hantel

Hematologic Oncologist, Ethicist, & Health Services Researcher @DanaFarber and Asst Prof @HarvardMed. Views expressed are my own.

[JAMA Oncology @JAMAOnc]

Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity.

https://t.co/3zfb0xfzFK

[NEJM @NEJM]

Andrew Hantel, MD, discusses a source of discrimination against some patients in cancer research and care practices. Full interview with NEJM Executive Managing Editor Stephen Morrissey (@srm128): https://t.co/2ROyFN7tx4

[NEJM @NEJM]

Hantel et al. write that cancer research and care practices that adversely affect people with the Duffy null phenotype are an underrecognized and widespread source of discrimination against people of African or Arab ancestry. Read the Perspective: https://t.co/aIvSTyYN4X

[J Mark Sloan @Jmarksloan]

There should be Duffy null specific values for:
-Dose modifications on and off trial
-CTCAE toxicities
-Remission criteria
-Clinical trial inclusion

>50% of trials require dose reductions within the Duffy null reference range.

@LaurenMerzMD @ahantel

https://t.co/kG8qZJw6QU

[Andrew Hantel @ahantel]

Our new article in @JAMANetworkOpen describes cancer trial eligibility and dose-modifications for individuals with Duffy null (DN) phenotype. 77% of trials & 54% of regimens excluded or modified doses for neutrophil counts within the DN reference range.

https://t.co/JTEpeIad7E

[Andrew Hantel @ahantel]

Excited to share our study on the environmental and downstream human health effects of tele-oncology and decentralized cancer care as an oral abstract @ASCO 2024 and simultaneously published in @JAMAOnc : https://t.co/T2eE3XxKnn @DFCIPopSci @DanaFarber

[Andrew Hantel @ahantel]

Grateful to have played a part in this guidance from @ASCO , now live in @JCO_ASCO .
https://t.co/4Wej6ZfoOF

[ASH @ASH_hematology]

A new study in @BloodAdvances highlights the need to address racial and ethnic #clinicaltrial enrollment disparities. Researchers say findings underscore need to create targeted diversification strategies to ensure representation. Read more: https://t.co/HcaL6xqD7K

[Blood Advances @BloodAdvances]

Article here: Racial and Ethnic Enrollment Disparities and Demographic Reporting Requirements in Acute Leukemia Clinical Trials https://t.co/uD6hQfkFfe

[Ryan Nipp, MD, MPH, MBA, FASCO @RyanNipp]

Interesting study demonstrates that gait speed correlates with survival but not treatment intensity recommendation in older adults with blood #cancer who presented for treatment.

https://t.co/LttQnlytiH

#GeriOnc #Geriatrics #PallOnc
@JournalCancer @myCARG @cdumonti @ahantel

[JAMA Oncology @JAMAOnc]

55% and 26% of US states' crisis standards of care guidelines deprioritized or excluded some patients with cancer during scarce resource allocation, respectively. States with NCI CCCs had higher odds of palliative care provisions & lower odds of exclusions https://t.co/xy5LZJTFEi

[UChicagoCancerCenter @UCCancerCenter]

Wendy Stock summarizes data presented in exciting session on AML, MDS & CLL prognosis & monitoring biomarkers #ASCO15

[Andrew Hantel @ahantel]

@MedChiefs The fringe benefits of UCIMR - a world renowned (and free!) medical ethics conference right on campus.